Market research
AGTC Applied Genetic
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 27M
- P/E ratio
- Not available
- Analyst target
- 0.34
- Dividend yield
- 0.0%
- Beta
- 1.58
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US03820J1007
- Market cap
- 27M
- P/E ratio
- Not available
- Analyst target
- 0.34
- Dividend yield
- 0.0%
- Beta
- 1.58
About
About Applied Genetic
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the AGTC discussion.
5 years, 4 months ago
Applied Genetic Technologies Corporation is currently in a long term downtrend where the price is trading 16.9% below its 200 day moving average.
From a valuation standpoint, the stock is 95.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 58.0.
Applied Genetic Technologies Corporation's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has dropped by 79.3% to $-15M since the same quarter in the previous year.
Finally, its free cash flow fell by 57.4% to $-14M since the same quarter in the previous year.
Based on the above factors, Applied Genetic Technologies Corporation gets an overall score of 1/5.